ICU Medical Inc.
Find Ratings ReportsICU MEDICAL INC's gross profit margin for the fourth quarter of its fiscal year 2023 is essentially unchanged when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. ICU MEDICAL INC has weak liquidity. Currently, the Quick Ratio is 0.86 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has remained virtually unchanged only increasing by 1.60% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
Income Statement | Q4 FY23 | Q4 FY22 |
---|---|---|
Net Sales ($mil) | 587.86 | 578.01 |
EBITDA ($mil) | 75.72 | 90.48 |
EBIT ($mil) | 18.56 | 33.67 |
Net Income ($mil) | -17.15 | -15.54 |
Balance Sheet | Q4 FY23 | Q4 FY22 |
---|---|---|
Cash & Equiv. ($mil) | 254.72 | 213.01 |
Total Assets ($mil) | 4378.44 | 4515.64 |
Total Debt ($mil) | 1704.72 | 1735.12 |
Equity ($mil) | 2123.41 | 2089.93 |
Profitability | Q4 FY23 | Q4 FY22 |
---|---|---|
Gross Profit Margin | 42.99 | 44.44 |
EBITDA Margin | 12.88 | 15.65 |
Operating Margin | 3.16 | 5.83 |
Sales Turnover | 0.52 | 0.5 |
Return on Assets | -0.67 | -1.64 |
Return on Equity | -1.4 | -3.55 |
Debt | Q4 FY23 | Q4 FY22 |
---|---|---|
Current Ratio | 2.53 | 2.5 |
Debt/Capital | 0.45 | 0.45 |
Interest Expense | 26.71 | 19.74 |
Interest Coverage | 0.7 | 1.71 |
Share Data | Q4 FY23 | Q4 FY22 |
---|---|---|
Shares outstanding (mil) | 24.14 | 23.99 |
Div / share | 0.0 | 0.0 |
EPS | -0.71 | -0.65 |
Book value / share | 87.96 | 87.11 |
Institutional Own % | n/a | n/a |
Avg Daily Volume | 275673.0 | 354178.0 |
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. For additional comparison, its price-to-book ratio of 1.12 indicates a significant discount versus the S&P 500 average of 4.68 and a significant discount versus the subsector average of 4.96. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, ICU MEDICAL INC proves to trade at a discount to investment alternatives.
Price/Earnings |
|
Price/Cash Flow |
| |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICUI NM | Peers 49.88 | ICUI 14.33 | Peers 33.16 | |||||||||||||||||||||
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings. ICUI's P/E is negative making this valuation measure meaningless. |
Discount. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures. ICUI is trading at a significant discount to its peers. |
|||||||||||||||||||||||
Price/Projected Earnings |
|
Price to Earnings/Growth |
|
|||||||||||||||||||||
ICUI 15.11 | Peers 24.07 | ICUI NA | Peers 0.91 | |||||||||||||||||||||
Discount. A lower price-to-projected earnings ratio than its peers can signify a less expensive stock or lower future growth expectations. ICUI is trading at a discount to its peers. |
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples. Ratio not available. |
|||||||||||||||||||||||
Price/Book |
|
Earnings Growth |
|
|||||||||||||||||||||
ICUI 1.12 | Peers 4.96 | ICUI 60.58 | Peers 126.83 | |||||||||||||||||||||
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet. ICUI is trading at a significant discount to its peers. |
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios. However, ICUI is expected to significantly trail its peers on the basis of its earnings growth rate. |
|||||||||||||||||||||||
Price/Sales |
|
Sales Growth |
|
|||||||||||||||||||||
ICUI 1.05 | Peers 6.41 | ICUI -0.92 | Peers 8.91 | |||||||||||||||||||||
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales. ICUI is trading at a significant discount to its subsector on this measurement. |
Lower. A sales growth rate that trails the subsector implies that a company is losing market share. ICUI significantly trails its peers on the basis of sales growth. |
|||||||||||||||||||||||